IFN-γ-Stimulated MSC Exosomes for Anti-Inflammatory Macrophage Induction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods for inducing anti-inflammatory macrophages from mesenchymal stem cells (MSCs) are inefficient, with a low delivery rate to the liver and unclear mechanisms for changing macrophage polarity, limiting their therapeutic effects in conditions like liver cirrhosis.

Innovation Solution

A method involving culturing macrophages with exosomes produced from MSCs stimulated with interferon gamma (IFN-γ) to induce anti-inflammatory macrophages, utilizing exosomes containing specific proteins such as Annexin A1, Lactadherin, Lactotransferrin, Galectin-3 binding protein, and Aminopeptidase N to shift macrophage polarity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If mesenchymal stem cells (MSCs) are administered intravenously to treat liver cirrhosis, then therapeutic effects are exhibited, but the delivery rate to the liver is low and the mechanism for changing macrophage polarity is unclear

Engineering Contradiction:

Improvetherapeutic effectVSAvoiddelivery rate to liver

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent extracts the active therapeutic components from MSCs by isolating exosomes that contain specific proteins (Annexin A1, Lactadherin, Lactotransferrin, Galectin-3 binding protein, and Aminopeptidase N). This extraction allows the therapeutic effect to be delivered without requiring large quantities of whole MSCs to reach the liver, as only the essential exosomal components are needed to induce anti-inflammatory macrophage polarization.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent introduces exosomes as intermediary carriers that mediate the interaction between MSCs and macrophages. These exosomes serve as the active substance that transfers the polarity-changing signal from MSCs to macrophages, replacing the need for direct MSC delivery and clarifying the mechanism through which MSCs exert their therapeutic effects on liver cirrhosis.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If conventional MSC culture methods are used, then cells can be cultured, but the efficiency of inducing anti-inflammatory macrophages is low

Engineering Contradiction:

Improveinduction efficiency of anti-inflammatory macrophagesVSAvoidtherapeutic effect consistency

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent changes the cultural parameters by specifying particular culture conditions for MSCs that optimize exosome production and composition. By controlling culture parameters to ensure exosomes contain the five key proteins, the method achieves high efficiency in inducing anti-inflammatory macrophages while maintaining consistent therapeutic effects across different batches.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS12350293B2Induction method for macrophage, anti-inflammatory macrophage-inducing agent, and pharmaceutical composition

Publication Date: 2025.07.08 NIIGATA UNIVERSITY

AI summary

An induction method for a macrophage is provided, in which macrophages are cultured in the presence of exosomes produced from a mesenchymal stem cell to which interferon gamma has been added and are induced into anti-inflammatory macrophages. An anti-inflammatory macrophage-inducing agent includes exosomes produced from a mesenchymal stem cell to which interferon gamma has been added, as an active component. A pharmaceutical composition contains the inducing agent.